Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.03
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of RAD.AX is 0.11 and suggests 244% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Data is available to registered users only
